BioDlink Champions Biologics Development Between Continents
Recognized for its excellence in the field of biologics, BioDlink stands out as a leader in contract development and manufacturing. The company recently made headlines at a major conference, showcasing its vital role in achieving a significant milestone: the approval of the world's first EGFR-targeted antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma.
A Breakthrough in Biologics
In a captivating keynote presentation titled "Linking Europe and China — Mutual Success in Biologics CMC Development," Dr. Jian Zhang, Chief Operating Officer at BioDlink, provided insights into the evolving biologics landscape. He revealed that as of 2025, China accounted for a staggering 54 percent of ADCs and 48 percent of bispecific and tri-specific antibodies in global clinical trials. This statistic reflects China's growing influence within the international biopharmaceutical market.
Financial Growth and License-Outs
Dr. Zhang's presentation also highlighted a remarkable increase in China’s licensing deals, with a total deal value reaching $920.3 billion in the first three quarters of 2025. This marked a significant 77 percent increase compared to the previous year, underlining the country's expanding role in global biopharmaceutical transactions.
Innovative Solutions for Global Clients
Dr. Zhang didn't just stop at discussing trends; he also showcased how BioDlink's integrated, end-to-end platform promotes sustainable success through seamless technology transfer and agile regulatory alignment. A standout achievement featured in his talks was the recent production of a Becotatug Vedotin injection, the first EGFR-targeted ADC to receive marketing approval from China’s National Medical Products Administration (NMPA). This achievement marks a significant therapeutic advancement in the R/M NPC treatment space.
Acknowledgment of Excellence
Further establishing its reputation, BioDlink was honored as Biologics CDMO of the Year at the prestigious Biologics CDMO Excellence Europe 2025 awards. This accolade signifies the company's commitment to delivering superior quality, speed, and cost-effectiveness to its customers.
Strategic Collaboration in Biologics
During the conference, BioDlink sponsored a forum titled "Tech-Transfer Simplified: Lessons across the Lifecycle," featuring Dr. Zhang in discussions with leaders from top biotech firms and multinational corporations. The emphasis was that technology transfer is more than merely sharing technical knowledge; it is a strategic process that impacts product quality, timelines, and regulatory outcomes. This approach is crucial in positioning China as a pivotal innovation hub, fostering accelerated development and licensing opportunities.
Empowering Global Clients
"We empower our global clients to innovate fearlessly," said Dr. Zhang. He emphasized BioDlink's strategic positioning with top-tier facilities in Asia and its robust reach into European markets. With proven quality systems, BioDlink stands as a vital link connecting Europe to China’s rapidly evolving drug discovery and CMC development ecosystem, offering both speed and cost advantages.
About BioDlink Biopharm Co., Ltd.
BioDlink (1875.HK) is a distinguished global CDMO dedicated to biologics and bioconjugates, including ADCs and XDCs. With its headquarters in Suzhou and additional sites in Shanghai and Beijing, the company provides comprehensive, integrated services from early-stage research and development to commercial manufacturing.
Equipped with a cutting-edge integrated platform and proprietary technologies, such as BDKcell for rapid cell line development and GL-DisacLink for site-specific conjugation, BioDlink clearly demonstrates its mission of enhancing partner development while optimizing efficiency and lowering costs.
The company operates four advanced commercial manufacturing lines, capable of large-scale sterile fill-finish operations, all supported by a globally aligned GMP-quality system recognized by authorities, including the PMDA in Japan. This robust framework has facilitated successful product approvals across various markets.
With a commitment to the guiding principles of "Quality First, Innovation Driven, Success Together," BioDlink is poised to broaden global access to next-generation biologics, forging trusted partnerships around the world.
Frequently Asked Questions
What recognition has BioDlink received for its work?
BioDlink was awarded the title of Biologics CDMO of the Year at the Biologics CDMO Excellence Europe 2025 awards, showcasing its excellence in the biologics sector.
What significant achievement was highlighted by Dr. Zhang?
Dr. Zhang emphasized the approval of the first EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma as a key milestone for BioDlink.
How does BioDlink facilitate technology transfer?
BioDlink utilizes an integrated platform that promotes seamless technology transfer, ensuring compliance and faster manufacturing timelines.
Where are BioDlink's manufacturing facilities located?
BioDlink's headquarters are in Suzhou, with additional centers in Shanghai and Beijing, allowing it to serve a global client base effectively.
What is BioDlink's mission in the biopharmaceutical industry?
BioDlink aims to advance global access to next-generation biologics while fostering trusted partnerships through quality and innovation.
